trending Market Intelligence /marketintelligence/en/news-insights/trending/U_a1XADP2KPon8OlRxokcg2 content esgSubNav
In This List

Approvals for AstraZeneca, Merck & Co.; designations for UroGen, Pfizer


Insight Weekly: US stock market downturn; Chinese bank earnings; Europe's big tech bills


Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds


Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall


Global M&A By the Numbers: Q1 2022

Approvals for AstraZeneca, Merck & Co.; designations for UroGen, Pfizer

Approvals and designations made by the U.S. Food and Drug Administration for the week ended Dec. 20.


* AstraZeneca PLC and Daiichi Sankyo Co. Ltd.'s Enhertu, for HER2-positive breast cancer that has spread across the body or has metastasized after receiving two or more therapies.

* Merck & Co. Inc.'s Ervebo, for preventing Ebola virus disease.

* Pfizer Inc. and Astellas Pharma Inc.'s Xtandi for metastatic castration-sensitive prostate cancer.

* Seattle Genetics Inc. and Astellas Pharma's Padcev for adult patients with locally advanced or spreading urothelial cancer who have not responded to a PD-1/L1 inhibitor and platinum-containing chemotherapy.

* Avadel Pharmaceuticals PLC's Nouress injection for neonatal patients that require total parenteral nutrition.

* Medtronic PLC's Stealth Autoguide robotic system for positioning assistance during neurosurgical procedures.

* Elekta AB (publ)'s Elekta Unity technology in diffusion-weighted imaging.

SNL ImageFDA headquarters in Silver Spring, Md.
Source: Associated Press

Priority review

* UroGen Pharma Ltd.'s UGN-101, for low-grade upper tract urothelial cancer.

* Pfizer's Braftovi, in combination with Eli Lilly and Co.'s Erbitux for its expanded use in treating patients with BRAF-mutant colorectal cancer who have received either one or two prior therapies.

Fast track

* Kura Oncology Inc.'s tipifarnib for patients with HRAS mutant head and neck squamous cell carcinomas after progression on platinum therapy.

* Salarius Pharmaceuticals Inc.'s seclidemstat for Ewing sarcoma.

Breakthrough therapy

* Agios Pharmaceuticals Inc.'s Tibsovo for relapsed or refractory myelodysplastic syndrome that have a mutation called isocitrate dehydrogenase 1, or IDH1.

* Seattle Genetics' tucatinib, in combination with Roche Holding AG's Herceptin and Xeloda for HER2-positive breast cancer patients whose disease has spread to nearby tissue or lymph nodes and cannot be surgically removed or has spread to other parts of the body.

Other designations

* Orphan drug, for Eagle Pharmaceuticals Inc.'s Ryanodex for organophosphate exposure.

* Orphan drug, for Prevail Therapeutics Inc.'s gene therapy PR006 for frontotemporal dementia patients with a GRN gene mutation.

* Orphan drug, for Cytokinetics Inc.'s reldesemtiv for amyotrophic lateral sclerosis.